JNJ-40411813

JNJ-40411813 is a positive allosteric modulator that binds an allosteric site on the mGlu2 receptor and increases its responsiveness to glutamate, amplifying presynaptic autoreceptor feedback that limits excessive glutamate release. In rodent models it displayed antipsychotic-like activity, inhibiting phencyclidine- and scopolamine-induced hyperlocomotion and conditioned avoidance behaviour, effects that overlapped with the orthosteric mGlu2/3 agonist LY404039; a rodent-specific metabolite also confers some 5-HT2A antagonism, adding a secondary pharmacology in those species ^[1]. Comparative studies suggested that mGlu2 activation alone is sufficient for activity in several antipsychotic models, supporting the allosteric strategy ^[1].

Clinically, JNJ-40411813 was evaluated as an adjunctive treatment for major depressive disorder with significant anxiety. In a phase 2a proof-of-concept study it did not meet its primary anxiety endpoint but produced signals of benefit across several secondary depression and anxiety measures while being well tolerated ^[2]. A companion review examined whether mGlu2 positive allosteric modulators can move forward for schizophrenia, weighing the mixed clinical translation of the mechanism against its favourable side-effect profile relative to dopamine antagonists ^[3]. JNJ-40411813 thus stands as a well-characterized clinical mGlu2 positive allosteric modulator that helped define both the promise and the limits of the approach.

Across its phase 2 programs JNJ-40411813 was generally well tolerated, without the metabolic, prolactin or movement side effects characteristic of dopamine-blocking antipsychotics. Its allosteric, activity-dependent mechanism was intended to reduce the risk of overstimulation and possibly the convulsion liability associated with full orthosteric agonists. As an investigational compound it is not approved and its long-term human safety is not fully established.

JNJ-40411813 arose from a collaboration between Addex Therapeutics, which contributed allosteric modulator discovery expertise, and Janssen, which advanced it into the clinic under the code ADX71149. It was tested in phase 2 for schizophrenia and for anxious depression in the early to mid 2010s. Although neither program delivered a clear positive primary outcome, the compound remained a reference mGlu2 positive allosteric modulator and informed continued interest in the target.

Among metabotropic glutamate researchers JNJ-40411813 is recognized as one of the most clinically advanced mGlu2 positive allosteric modulators and a key data point in the debate over whether allosteric modulation can succeed where orthosteric agonism faltered. It is frequently cited in reviews of glutamatergic psychiatry. It is known to scientists and informed followers of the field rather than used as a consumer nootropic.